Current Headlines

  1. New CDISC Data Standard Aids Development Of Therapies For Ebola Virus
    3/23/2017

    The Clinical Data Interchange Standards Consortium (CDISC) and the Infectious Diseases Data Observatory (IDDO) announce the availability of a new standard to assist in the collection, aggregation and analysis of Ebola virus disease (EVD) research data

  2. Fabric Genomics Enters Strategic Partnership With Veritas Genetics
    3/22/2017

    Fabric Genomics , a global computational genomics company, and Veritas Genetics, the global leader in genetic sequencing and interpretation, announced recently at the ACMG Annual Clinical Genetics Meeting that they have entered into a technology partnership

  3. U.S. National Laboratory Research Payloads Prepped And Ready For Orbital ATK CRS-7 Launch To The Space Station
    3/22/2017

    The Orbital ATK Cygnus vehicle is slated to launch its seventh cargo resupply mission (CRS-7) to the International Space Station (ISS) no earlier than March 27, 2017 onboard United Launch Alliance's Atlas V vehicle, carrying more than 40 ISS U.S. National Laboratory sponsored investigations

  4. U.K. Biobank, Regeneron And GSK Announce Largest Gene Sequencing Initiative On World's Most Detailed Health Database To Improve Drug Discovery And Disease Diagnosis
    3/22/2017

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a major research initiative among the Regeneron Genetics Center (RGC), U.K. Biobank and GSK to generate genetic sequence data from the 500,000 volunteer participants in the U.K. Biobank resource

  5. FDA Approves Xadago (Safinamide) For Parkinson’s Disease (PD) Patients
    3/21/2017

    Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain, and its partners Zambon S.p.A. and US WorldMeds, LLC, announced recently that the Food and Drug Administration (FDA) has approved the use of Xadago (safinamide) for the treatment of Parkinson’s disease as add-on therapy to levodopa/carbidopa

  6. X-Chem And Ono Enter Into Multi-Target Drug Discovery Collaboration
    3/21/2017

    X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, recently announced a partnership with Ono Pharmaceutical Co., Ltd. (Ono)

  7. Sound Pharmaceuticals Announces $1.6M Award From Cystic Fibrosis Foundation Therapeutics To Prevent And Treat The Hearing Loss And Tinnitus Associated With Antibiotic Use
    3/21/2017

    Sound Pharmaceuticals, Inc., (SPI) is pleased to announce that it has been awarded up to $1.6M from Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation

  8. Medicinal Cannabis Applications Target the Development Of Enhanced Therapies And Treatments For Various Health Disorders
    3/21/2017

    Recent studies concerning the therapeutic attributes of Cannabidiol (CBD) have pointed to growing evidence to suggest that it could help in the treatment of anxiety-related and other health disorders

  9. RedHill Biopharma Announces First Patient Dosed In The Open-Label Extension Study To The Phase III Study With RHB-104 For Crohn’s Disease
    3/21/2017

    RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced dosing of the first patient in the open-label extension study to the Phase III study with RHB-104 for the treatment of Crohn’s Disease (the MAP US study).

  10. NantKwest Announces FDA Grant Of Orphan Drug Designation For The Company’s aNK Natural Killer Cell Therapy In Merkel Cell Carcinoma
    3/20/2017

    NantKwest, Inc., a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, announced recently that the FDA has granted Orphan Drug Designation to the company’s activated natural killer (aNK) cell therapy for treatment of patients with advanced Merkel cell carcinoma